HBAN:SIX

Helvetia Baloise Holding AG

Data as of 2026-03-11 - not real-time

$15.99

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Huntington Bancshares trades at a price that aligns closely with its discounted cash flow estimate, suggesting a material upside potential compared with analyst price targets. The stock benefits from a low price‑to‑earnings multiple relative to its industry peers and a dividend yield that ranks among the higher tier in the regional banking sector, while the payout ratio remains comfortably below the threshold that would jeopardize sustainability. Recent earnings have beat expectations, and revenue growth remains in double‑digit territory, reinforcing the positive earnings momentum highlighted by a consensus of buy recommendations.
On the technical side, the relative strength index sits in oversold territory, providing a short‑term catalyst for price appreciation, whereas the moving averages indicate a neutral stance and the MACD remains bearish, tempering expectations of a rapid rally. Volatility is elevated and beta is modestly above one, reflecting sensitivity to broader market swings, while decreasing volume and a clear support level suggest caution. Overall, the blend of attractive valuation, solid dividend profile, and earnings resilience supports a favorable outlook, but investors should remain mindful of sector‑specific regulatory and economic headwinds.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Oversold RSI indicating near‑term price support
  • High dividend yield with sustainable payout
  • Potential upside relative to fair value estimate

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth and earnings beat reinforcing earnings momentum
  • Analyst consensus leaning toward buy
  • Valuation gap between current price and analyst targets

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Steady dividend income stream
  • Balanced growth and value characteristics
  • Sector and regulatory risks tempering aggressive positioning

Key Metrics & Analysis

Financial Health

Revenue Growth10.30%
Profit Margin28.74%
P/E Ratio11.5
ROE10.10%
ROA1.04%
P/B Ratio1.2
Op. Cash Flow$2.5B
Industry P/E17.3

Technical Analysis

TrendNeutral
RSI33.5
Support$15.58
Resistance$19.01
MA 20$17.18
MA 50$17.65
MA 200$16.85
MACDBearish
VolumeDecreasing
Fear & Greed Index76.91

Valuation

Fair Value$15.99
Target Price$20.64
Upside/Downside29.10%
GradeUndervalued
TypeBlend
Dividend Yield3.85%

Risk Assessment

Beta1.14
Volatility34.01%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.